HHU.F ALLERGY THER. PLC LS-001
- Market cap
- EUR 57.5M
- P/E
- -
- P/B
- 9.98x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2025.
Is HHU.F undervalued?
Graham numberThe Graham number of ALLERGY THER. PLC LS-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ALLERGY THER. PLC LS-001 fundamental analysis
No fundamental analysis for ALLERGY THER. PLC LS-001 yet.
ALLERGY THER. PLC LS-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ALLERGY THER. PLC LS-001
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venom…
Full company profileALLERGY THER. PLC LS-001 financial statements
ALLERGY THER. PLC LS-001 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 72.8M | 59.6M | 55.2M | 55.0M |
| Gross Profit | 49.5M | 33.2M | 29.7M | 29.3M |
| Operating Income | -12.2M | -34.9M | -34.0M | -28.2M |
| EBITDA | -7.82M | -35.1M | -30.7M | -28.3M |
| Net Income | -13.8M | -43.1M | -38.6M | -40.1M |
| EPS | -0.02 | -0.06 | -0.01 | -0.01 |
| Balance Sheet | ||||
| Total Assets | 72.9M | 68.4M | 66.4M | 67.5M |
| Total Liabilities | 35.2M | 64.3M | 59.0M | 95.7M |
| Shareholders' Equity | 37.8M | 4.11M | 7.36M | -28.2M |
| Cash & Short-term Investments | 20.3M | 14.6M | 12.7M | 12.6M |
| Cash Flow | ||||
| Operating Cash Flow | -14.0M | -28.9M | -32.1M | -28.1M |
| Capital Expenditure | 3.06M | 4.67M | 3.40M | 3.42M |
| Free Cash Flow | -17.1M | -33.6M | -35.5M | -31.5M |
| Ratios | ||||
| ROE | -36.5% | -1,048.2% | -525.0% | - |
| ROA | -18.9% | -62.9% | -58.2% | -59.4% |
| Net Profit Margin | -18.9% | -72.3% | -70.0% | -72.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ALLERGY THER. PLC LS-001 dividends
ALLERGY THER. PLC LS-001 has not paid dividends in the last 4 fiscal years.
Who owns ALLERGY THER. PLC LS-001
- Insiders 88.78%
- Institutions 0.01%
- Public & others 11.22%
- Shares outstanding 6.33B
- Free float 702M
ALLERGY THER. PLC LS-001 company profile
- Company name
- ALLERGY THER. PLC LS-001
- Ticker
- HHU.F
- ISIN
- GB00B02LCQ05
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 584
- Fiscal year end
- June
- Address
- Dominion Way, Worthing, United Kingdom, BN14 8SA
- Phone
- 44 1903 844 700
- Website
- allergytherapeutics.com
About ALLERGY THER. PLC LS-001
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
ALLERGY THER. PLC LS-001 management
10- Mr. Manuel LlobetCEO & Executive Director · born 1965
- Dr. Shaun Antony FurlongCFO & Executive Director · born 1976
- Mr. Helge Weiner-TrapnessChief Strategy Officer & Executive Chairman · born 1963
- Dr. Murray SkinnerChief Scientific Officer
- Ms. Sue BakerHead of Human Resources
- Simon PiggottHead of Clinical Science
- Mr. Alan BullimoreHead of Communication & Market Development
- Mr. Russell PicketGroup Financial Controller
- Ms. Karley Charlotte Mouatt CheesmanCompany Secretary
- Mr. Matthew HeathPrincipal Scientist